Cabaletta Bio price target raised to $25 from $23 at Guggenheim

Guggenheim raised the firm’s price target on Cabaletta Bio (CABA) to $25 from $23 and keeps a Buy rating on the shares. After having touched base with management following the company’s Q1 report, the firm argues that the ability of Cabaletta to align with FDA on “an efficient trial design significantly smaller and potentially faster than competitors” and with the potential for a broad label reinforces the firm’s conviction in the company’s strategic direction.